News Detail

Molecular Partners elects Clare Fisher to board of directors at AGM

PUBT · 2d ago

Listen to the news

Molecular Partners elects Clare Fisher to board of directors at AGM

Molecular Partners shareholders elected Clare Fisher to board at annual general meeting.
Fisher is SVP, global business development and M&A at BeOne Medicines.
Her prior roles include chief business officer at Kaleido.
Steven H. Holtzman will leave board following decision not to stand for re-election.
Board re-elected Bill Burns as chairman.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604141600OMX_____CNEWS_EN_GNW9689597_en) on April 14, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.